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CancerHeat shock protein 90 (Hsp90) has recently emerged as an attractive therapeutic target in cancer treatment
because of its role in stabilizing the active formof awide range of client oncoproteins. This study investigated the
mechanism of apoptosis induced by the purine-scaffold Hsp90 inhibitor PU-H71 in different human cancer cell
lines and examined the role of Bcl-2 and Bax in this process. We demonstrated that Hsp90 inhibition by
PU-H71 generated endoplasmic reticulum (ER) stress and activated the Unfolded Protein Response (UPR) as
evidenced by XBP1 mRNA splicing and up-regulation of Grp94, Grp78, ATF4 and CHOP. In response to
PU-H71-induced ER stress, apoptosis was triggered in melanoma, cervix, colon, liver and lung cancer cells, but
not in normal human ﬁbroblasts. Apoptosis was executed through the mitochondrial pathway as shown by
down-regulation of Bcl-2, up-regulation and activation of Bax, permeabilization of mitochondrial membranes,
release of cytochrome c and activation of caspases.We also found that, in contrast to the ER stressor thapsigargin,
PU-H71 induced apoptosis in cells overexpressing Bcl-2 and thus overcame the resistance conferred by this
anti-apoptotic protein. In addition, although Bax deﬁciency rendered cells resistant to PU-H71, combined treat-
ment with the anticancer drugs cisplatin or melphalan greatly sensitized these cells to PU-H71. Taken together,
these data suggest that inhibition of Hsp90 by PU-H71 is a promising strategy for cancer treatment, particularly
in the case of tumors resistant to conventional chemotherapy.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The evolutionary conserved chaperone heat shock protein 90
(Hsp90) is essential for the maturation, activation and stability of
cellular proteins, termed clients, mainly involved in the regulation
of proliferation, cell cycle progression and survival [1,2]. Hsp90 is
one of the most abundant molecular chaperones constituting 1–2% of
total cellular proteins under non-stressed conditions and increasing to
4–6% under stress [3]. In cancer cells, the expression and activity of
this ATP-dependent chaperone were demonstrated to increase [4],
thus promoting the stabilization of the aberrant conformation ofal transmembrane potential;
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l rights reserved.mutant proteins. The ability of this chaperone to stabilize the active
form of a wide range of client oncoproteins has made Hsp90 a novel
and attractive target for anticancer therapy and has led to the devel-
opment of many Hsp90 inhibitors that inhibit the intrinsic ATPase
activity of Hsp90. The most studied of these compounds are the natural
antibiotic geldanamycin and its derivatives 17-N-Allylamino-17-
demethoxygeldanamycin (17-AAG) and 17-dimethylaminoethylamino-
17-demethoxygeldanamycin (17-DMAG). Clinical studies with these
inhibitors have shown limited efﬁcacy and unacceptable side effects
often attributed to the benzoquinone moiety of these molecules [5]. To
avoid off-target toxicity, Chiosis and collaborators have designed novel
inhibitors using purine as a scaffold [6]. Among these, PU-H71 was iden-
tiﬁed as a potent inducer of apoptosis in breast tumor, B cell lymphoma,
hepatocellular carcinoma and myeloma [7–10]. Although the mecha-
nisms underlying the pro-apoptotic effects of PU-H71-induced apo-
ptosis need further investigation, this Hsp90 inhibitor was reported
to trigger caspase activation, PARP cleavage and Akt inactivation in
multidrug resistant and triple-negative breast cancer cells [8,11].
Apoptosis is a highly regulated cell death program triggered
through the extrinsic (or death receptors) pathway or the intrinsic
(or mitochondrial) pathway. The mitochondrial pathway involves
mitochondria as central integrators and coordinators of the apoptotic
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abilization (MMP), which is due to the opening of pores formed by
Bcl-2 family members, cardiolipin and/or the mitochondrial perme-
ability transition pore (PTP). MMP leads to dissipation of the mito-
chondrial transmembrane potential (ΔΨm), release of pro-apoptotic
proteins (e.g. cytochrome c, AIF) from the intermembrane space to
the cytosol, subsequent caspase cascade activation, DNA fragmentation
and cell dismantling [12]. Bcl-2 family proteins, which have either
pro- (Bax, Bak, Bad…) or anti-apoptotic (Bcl-2, Bcl-xL…) activities,
have been involved as crucial regulators of MMP. The mitochondrial
pathway of apoptosis is usually triggered by intracellular stimuli
(viral proteins, chemotherapeutic drugs…) or signals emanating
from other organelles such as the endoplasmic reticulum (ER) [13].
Disruption of ER homeostasis induces ER stress which in turn
leads to the Unfolded Protein Response (UPR), a pro-survival process
induced to restore normal ER function. TheUPR is initiated by activation
of three proximal sensors: the PERK kinase, the transcription factor
ATF6 and the kinase/endoribonuclease IRE1, which are normally kept
inactive through the interaction with the ER-resident chaperone
Grp78/BiP [14]. Upon activation, these sensors lead to the increase of
ER chaperones (e.g. Grp78 and Grp94) and to the transcription of UPR
target genes (e.g. ATF4, XBP1 and CHOP). However, in the case of
prolonged or severe ER stress, the mitochondrial apoptotic process is
triggered to eliminate damaged cells [15]. ER stress-dependent apoptosis
was reported to be mediated mainly by the pro-apoptotic transcription
factor CHOP, pro-apoptotic members of the Bcl-2 family and direct
calcium transfer from ER to mitochondria at contact sites between
the two organelles [16,17]. Therefore, targeting ER stress and com-
ponents of the UPR is a promising strategy for cancer treatment. In-
terestingly, Hsp90 has been demonstrated to be an important
component of the transcriptional arm of the UPR, as it associates with
IRE1 and PERK to maintain their stability [18]. In addition, inhibition
of the molecular chaperone function of Hsp90 by geldanamycin or
17-AAG was reported to induce ER stress-mediated apoptosis in differ-
ent cell lines [19–21].
Little is known about the molecular mechanisms implicated in the
apoptotic pathway triggered by Hsp90 inhibition in response to
PU-H71. In this study, we investigated the involvement of ER stress
and mitochondrial pathways in PU-H71-induced apoptosis in different
human cancer cell lines. We also determined the role of Bcl-2 and Bax
and the ability of anticancer drugs cisplatin and melphalan to sensitize
resistant cancer cells to PU-H71 treatment.
2. Material and methods
2.1. Cells, cell culture and reagents
Human HeLa cervical cancer cells stably transfected with the
human bcl-2 gene or with the cytomegalovirus UL37 exon 1 gene
coding for vMIA or with the pcDNA3.1 vector containing the neomycin
resistance gene were generously given by Dr V. Goldmacher
(ImmunoGen, Cambridge, MA, USA). Human colon cancer cell lines
HCT116 Bax wild type and Bax K.O. (HCT116 Bax−) were generously
provided by Dr B. Vogelstein (Johns Hopkins University School of Med-
icine, Baltimore,MD,USA). Humanmelanoma cell lineMel501was kind-
ly given by Dr L. Larue (Institut Curie, Orsay, France). Normal human
ﬁbroblasts, generously provided by Dr A. Lombes (Institut Cochin,
Paris, France), were obtained from the tissue repository of the AFM
(Association Française contre les Myopathies). Human lung (A549)
and human hepatocellular (HepG2) carcinoma cell lines were pur-
chased from ECACC (Salisbury, UK). Cells were cultured in DMEM:F12
medium supplemented with 100 U/ml penicillin, 100 mg/ml strep-
tomycin, 1% glutamax (Invitrogen, Villebon sur Yvette, France) and
10% FBS (Lonza, Levallois-Perret, France), at 37 °C under 5% CO2/95%
air. PU-H71 (#P0030) was purchased from Sigma-Aldrich (Lyon,
France). The caspase inhibitor z-VAD-fmk was obtained from Bachem(GmbH, Germany). Calpain inhibitors ALLN and ALLM were from
Merck Millipore (Fontenay-sous-Bois, France). All other chemicals
were purchased from Sigma-Aldrich. DEVD-NucView™ 488 caspase-3
substrate was from Interchim (Montluçon, France). All other ﬂuores-
cent probes were from Invitrogen.
2.2. Flow cytometry analysis
For ﬂow cytometry analysis of mitochondrial transmembrane po-
tential (ΔΨm), cells were stained with 100 nM DiOC6(3) for 20 min
at 37 °C. Necrosis was estimated by adding 10 μg/ml of propidium
iodide (PI) just before analysis. PTP opening was assessed as de-
scribed previously [22]. Brieﬂy, cells were preincubated for 15 min
at 37 °C with 1 μM calcein-AM/100 μM CoCl2 in HBSS (Invitrogen)
supplemented with 1 mM HEPES, pH 7.3. HBSS was then replaced
by complete culture medium during apoptosis induction. The ﬂuores-
cent probe ﬂuorescein diacetate (FDA) was used to assess cell viability.
After treatment, cells were incubated for 5 min at 37 °C with FDA at
0.2 μg/ml. Caspase-3 activation was assessed using DEVD-NucView
488 caspase-3 substrate. After treatment, cells were incubated with
5 μM DEVD-NucView 488 for 30 min at RT before cytometric analysis.
Fluorescence of cells was analyzed on a Cell Lab Quanta MPL cytometer
(Beckman Coulter, Villepinte, France).
2.3. Sample preparation for transmission electron microscopy
Cells were ﬁxed with 2% glutaraldehyde/0.1 M sodium cacodylate
for 1 h at RT, pelleted and rinsed with 0.1 M sodium cacodylate/0.2 M
sucrose for 1 h. Samples were epon-embedded, sliced, mounted on
slides and the images were obtained at the electron microscopy facility
of INRA (Jouy-en-Josas, France).
2.4. Immunoﬂuorescence analysis
To examine the intracellular localization of cytochrome c and the
activation of Bax, cells were seeded on slides in six-well multidishes,
treatedwith PU-H71, washed in PBS 1×, ﬁxed in 3.7% paraformaldehyde
for 10 min at RT and permeabilized for 3 min in acetone at−20 °C. Cells
were saturated in PBS/3% bovine serum albumin (BSA) for 30 min and
incubated for 1 h with anti-cytochrome c (mAb 6H2.B4, BD Biosciences,
Le Pont de Claix, France) or anti-activated Bax (6A7, Sigma-Aldrich) in
PBS/1% BSA at RT. After two washes, the secondary antibody (Jackson
ImmunoResearch, Suffolk, England) was added in PBS/1% BSA. To detect
apoptotic cells, nuclei were stained with 2.5 μg/ml Hoechst 33348 for
5 min. Micrographs were taken on a Leica ﬂuorescence microscope
(Leica Microsystems, Nanterre, France).
2.5. RNA isolation and real-time reverse transcription polymerase
chain reaction
RNA was isolated from cultured cells using Zymo Research
QuickRNA MiniPrep according to the manufacturer's instructions.
Total RNA (1 μg) was reverse transcribed using BioRad iScript re-
verse transcription kit. For real-time PCR, cDNA was ampliﬁed by
the “two-step” SsoFast EvaGreen supermix (BioRad), heated at
95 °C for 30 s, then 50 cycles of denaturation at 95 °C during 2 s and
hybridization/elongation at 60 °C during 5 s. The PCR primers were
obtained from Euroﬁns: 5′GTCCCTCCAACAACAGCAAG3′(F) and 5′
AGGTCATCTGGCATGGTTTC3′(R) for atf4; 5′TGCTGAGTCCGCAGCAG
GTG3′(F) and 5′GCTGGCAGGCTCTGGGGAAG3′(R) for spliced xbp1 as
described by van Schadewijk et al. [23]; 5′AGCGACAGAGCCAAAA
TCAG3′(F) and 5′ACAAGTTGGCAAGCTGGTCT 3′(R) for chop. The results
were quantiﬁed according to the Cq value method, where Cq is deﬁned
as the quantiﬁcation cycle of PCR at which the ampliﬁed product is
detected. The ratio (1+Etarget gene)^−(Cq sample−Cq control)target
gene/(1+Ereference gene)^−(Cq sample−Cq control)reference gene was
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Fig. 1. PU-H71 induces ER stress and the UPR in HeLa cells. (A) HeLa cells were incubated
for 6 h with increasing concentrations of PU-H71 as indicated and protein levels of the ER
stressmarkers Grp94 andGrp78were analyzed bywesternblot. The level of CHOPprotein
was determined after 16 h of treatment. β-Actin was used as a loading control. RD: rela-
tive density as described in the Material and methods. (B) After 3 h of treatment of
HeLa cells with 1 μM PU-H71, the relative mRNA levels of the UPR target genes ATF4,
spliced XBP1 (XBP1s) and CHOP were quantiﬁed by qRT-PCR and expressed as fold
change over untreated controls. Values represent mean±SD of three independent exper-
iments. The dashed line represents no change (one-fold change) over the controls.
*Pb0.05, **Pb0.01, compared to control by paired Student's t-test.
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tion. With this calculation, expression of control was equivalent to one.
2.6. Western blot analysis
Cellswere lysed in RIPA lysis buffer (50 mMTris–HCl pH 8, 150 mM
NaCl, 1% Triton, 1 mM EDTA, 0.1% SDS, 0.5% deoxycholic acid) plus a
cocktail of protease inhibitors (Roche) and PMSF for 30 min at 4 °C.
Proteins (30 μg) were separated by SDS-polyacrylamide gel electro-
phoresis and transferred to PVDF membranes (Merck Millipore).
Membranes were incubated overnight at 4 °C with the following an-
tibodies: anti-Grp94 from Cell Signaling, and anti-Grp78, anti-Bax,
anti-Bcl-2, anti-CHOP and anti-β-actin from Santa Cruz. Proteins
were detected on a ChemiDoc XRS (BioRad) by using the ECLmethod
according to the manufacturer's instructions (Merck Millipore). To
calculate the relative density (RD), ImageJ software was used and the in-
tensity of each protein was normalized to β-actin. The data obtained
were then expressed as the ratio of the intensity of the protein in treated
cells to that of the corresponding protein in untreated cells (Co.).
2.7. Statistical analysis
All data are presented as mean±SD. Data were analyzed using
Prism 4 (GraphPad version 4.03, La Jolla, CA, USA). One-way ANOVA
was used to assess differences among groups followed by Dunnett's
post hoc test. When two groups were compared, differences were
assessed by Student's t-test. Differences between groups were consid-
ered signiﬁcant if the P value was less than 0.05.
3. Results
3.1. Hsp90 inhibition by PU-H71 generates ER stress and leads to activation
of the UPR
It has been shown that the ER stress sensors IRE1 and PERK are client
proteins of Hsp90 [18]. We have, therefore, investigated whether ER
stress and UPR are activated in response to the synthetic inhibitor
PU-H71 in cancer cells. HeLa cervical carcinoma cells were incubated
with PU-H71 and the expression of chaperones and UPR target genes
was measured by western blot and quantitative RT-PCR (Fig. 1). After
6 h of treatment with PU-H71, we observed a concentration-
dependent increase in the level of the ER-resident chaperones Grp94
(also known as gp96 or endoplasmin) and Grp78, two well-known
ER-stress markers (Fig. 1A). Because the UPR is an early cellular re-
sponse to ER stress, we analyzed the expression of UPR genes after
3 h of treatment. PU-H71 induced the up-regulation of ATF4, involved
in the PERK branch of the UPR, and the splicing of XBP1, indicative of
IRE1 activation (Fig. 1B). In addition, Hsp90 inhibition increased by
about 4.7-fold the expression of CHOP, a major component of the ER
stress-mediated apoptosis pathway. The increase of CHOPwas also con-
ﬁrmed at the protein level in response to PU-H71 (Fig. 1A). Taken to-
gether, these results indicate that PU-H71 induces ER stress and
activates different branches of the UPR in HeLa cells.
3.2. PU-H71 induces cell death through the mitochondrial pathway
of apoptosis
Up-regulation of the ER stress-associated apoptosis factor CHOP
prompted us to determine the signaling pathway involved in
PU-H71-induced cell death. Ultrastructural studies were carried out
by transmission electron microscopy to assess the effect of PU-H71 on
mitochondria and ER morphology. In the absence of treatment
(Fig. 2A, control), mitochondria displayed a classical shape with the
presence of cristae and some contact sites between ER and mitochon-
dria were visualized. Following treatment with 1 μM PU-H71, the ER
appeared more swollen and dilated, mitochondria were spherical inshape, devoid of cristae and local rupture of their membrane was ob-
served. In addition, the number of close appositions between ER and
mitochondria was increased. Of note, the structure of the Golgi appara-
tus appeared normal, indicating that, by contrast to ER and mitochon-
dria, this organelle was not affected by PU-H71 treatment. These data
suggest that PU-H71-induced ER stress promotes ER-mitochondria in-
teractions and lethal crosstalk between the two organelles. To measure
cell death, HeLa cells were incubatedwith PU-H71 for 40 h, labeledwith
ﬂuorescein diacetate (FDA), a cell viability marker, and analyzed by ﬂow
cytometry. A loss of ﬂuorescence of FDA occurs when cellular esterases
become inactive in the late steps of the cell death process. As reported
in Fig. 2B, PU-H71 elicited a rise in the percentage of dead cells with in-
active esterases to the same extent as the well-known ER stress inducer
thapsigargin (TG, 3 μM). To further characterize the cell death involved
in response to PU-H71 and assess the role of mitochondria, HeLa cells
were analyzed by ﬂow cytometry after staining with propidium iodide
to evaluate necrosis, DiOC6(3) to measure mitochondrial transmem-
brane potential (ΔΨm) and calcein/cobalt to determine PTP opening.
As shown in Fig. 2C, the percentage of PI high cells remained very low
(less than 10%), excluding the involvement of necrosis in PU-H71-
induced cell death. In addition, immunoﬂuorescence analysis showed
that PU-H71-treated cells exhibited condensed and fragmented nuclei
which are indicative of cells undergoing apoptosis (Fig. 2D, white ar-
rowheads). Besides, the increase in the percentage of calcein low cells
and DiOC6(3) low cells indicated the opening of PTP and the dissipation
of the mitochondrial transmembrane potential in response to PU-H71
and TG treatments. By deﬁnition, upon membrane permeabilization,
mitochondria release apoptogenic factors from the intermembrane
space to the cytoplasm. The subcellular localization of cytochrome c
was thus investigated in response to PU-H71. The immunoﬂuorescence
analyses (Fig. 2D) revealed that after treatment with this Hsp90
AB
Co
nt
ro
l
PU
-H
71
C
D Nuclei Cytochrome c Merge
10 µm 
0
10
20
30
40
Co. TG PU-H71
FD
A
 lo
w
 c
el
ls
 (%
) **
*
0
20
40
60
80
Co. TG PU-H71
Pe
rc
en
ta
ge
 o
f c
el
ls PI high
DiOC6(3) low
Calcein low
**
**
**
**
**
Control
500 nm 
Nu
PU-H71
500 nm 
M
R
G
M
R
Fig. 2. PU-H71 increases ER-mitochondria interactions and triggers the mitochondrial pathway of apoptosis. (A) Morphological changes of ER and mitochondria induced by 1 μM
PU-H71 were analyzed by transmission electron microscopy after 32 h of treatment. M: mitochondrion, R: endoplasmic reticulum, G: Golgi apparatus, Nu: nucleus, black arrowheads:
ER-mitochondrion contact site. (B and C) HeLa cells were treated with 1 μM PU-H71 or 3 μM TG (as a positive control) for 40 h. (B) Cell viability was determined by ﬂow cytometry
using the FDA assay and expressed as percentages of dead cells (FDA low cells). (C) Necrosis (PI high), ΔΨm loss (DiOC6(3) low) and PTP opening (calcein low) were analyzed by
ﬂow cytometry. (D) HeLa cells were left untreated (control) or were treated with 1 μM PU-H71 for 40 h, and cytochrome c localization was assessed by immunoﬂuorescence using
anti-cytochrome c antibody. Apoptotic cells (white arrows) were identiﬁed by Hoechst staining as cells presenting bright condensed or fragmented nucleus. Data in the bar
graphs represent mean±SD (n=4). *Pb0.05, **Pb0.01 by one-way ANOVA/Dunnett's post-test versus control.
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space protein cytochrome c (control) became diffuse in apoptotic
cells presenting a condensed or fragmented nucleus (PU-H71, white ar-
rowheads), indicating the release of cytochrome c frommitochondria to
the cytoplasm. Altogether, these results demonstrate the induction of
the mitochondrial pathway of apoptosis in HeLa cells in response to
PU-H71 treatment.
3.3. PU-H71-induced apoptosis requires caspase but not calpain activation
We next examined the involvement of caspases and calpains in
the apoptotic process triggered by PU-H71. HeLa cells were incubated
with PU-H71 (1 μM) or TG (3 μM) for 40 h, labeled with theDEVD-NucView 488 caspase-3 substrate, which becomes ﬂuorescent
when cleaved by active caspase-3, and analyzed by ﬂow cytometry
(Fig. 3A). We observed that PU-H71 and the ER-stressor TG triggered
a similar increase in the percentage of cells with activated caspase-3.
The pre-treatment of cells with zVAD (50 μM, 2 h), a pan-caspase in-
hibitor, completely protected HeLa cells from PU-H71-induced
caspase-3 activation (Fig. 3B) and cell death (Fig. 3C). By contrast,
no signiﬁcant difference in the percentage of active caspase-3 cells or
in FDA low cells was observed in the presence of the calpain inhibitors
ALLN (Fig. 3D) or ALLM (Fig. 3E), showing that calpains are not impli-
cated in PU-H71-induced apoptosis. These observations suggest that
caspases, but not calpains, are involved in the apoptotic process
triggered by PU-H71.
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Fig. 3. PU-H71 induces a caspase-dependent apoptotic process in HeLa cells. (A–E) Cells were incubated for 40 h with 1 μM PU-H71, stained with DEVD-NucView 488 caspase-3
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different human cancer cell lines but not in normal human ﬁbroblasts
We next determined whether the effects of Hsp90 inhibition by
PU-H71 observed in HeLa cells can be extended to other human cancer
cell lines. To this aim, HCT116 (colon carcinoma), A549 (lung carcinoma),
Mel501 (melanoma) and HepG2 (liver carcinoma) cells were incubated
for 40 h with PU-H71 (1 μM) and ER stress (increase in CHOP expres-
sion), dissipation of ΔΨm (DiOC6(3) low cells), activation of caspase-3
(active caspase-3) and cell death (FDA low cells) were analyzed
(Fig. 4). In all cell lines, an increase in CHOP mRNA and protein levels
was observed in response to PU-H71 (Fig. 4A). In addition, treatment of
cancer cellswith PU-H71 signiﬁcantly induced an increase in the percent-
age of DiOC6(3) low cells, active caspase-3 cells and FDA low cells
(Fig. 4B–E). These results demonstrated that PU-H71 elicited ΔΨm loss,
caspase activation and cell death in all cancer cell lines tested. We thus
wondered whether PU-H71 would also trigger cell death in normal
human cells. Normal human ﬁbroblasts were incubated with PU-H71
(1 μM) for 40 h (Fig. 4F) or with H2O2 (300 μM) for 24 h as a control
(Fig. 4G). Incubation of ﬁbroblasts with H2O2 resulted in a strong
augmentation of the percentage of DiOC6(3) low cells and FDA low
cells, whereas no signiﬁcant difference was observed between control
and PU-H71-treated cells, indicating that ﬁbroblasts are resistant toPU-H71. Altogether these data demonstrate that PU-H71 triggers ER
stress-dependent activation of the mitochondrial apoptotic pathway
in cancer cells of different origins, but not in normal human cells.3.5. PU-H71 overcomes Bcl-2-mediated resistance to apoptosis in HeLa cells
We examined the role of Bcl-2 and vMIA (viral mitochondrial in-
hibitor of apoptosis), two well-known inhibitors of the mitochondrial
pathway of apoptosis [24,25], in the regulation of PU-H71-induced
cell death. To determine the effect of PU-H71 on the expression of
Bcl-2 protein, western blot experiments were carried out. As shown
in Fig. 5A, PU-H71 decreased the level of the anti-apoptotic protein
Bcl-2 in a time-dependent manner in parental HeLa cells (HeLa neo)
but not in HeLa cells overexpressing Bcl-2 (HeLa Bcl-2). Flow
cytometric analyses were then performed to compare the response
of HeLa neo cells to HeLa cells stably overexpressing either Bcl-2
(HeLa Bcl-2) or vMIA (HeLa vMIA). Cell lines were incubated with
PU-H71 (1 μM) or TG (3 μM) and stained with either DiOC6(3) or
DEVD-NucView 488. The overexpression of vMIA totally inhibited the
loss of ΔΨm (Fig. 5B) and the activation of caspase-3 (Fig. 5C) induced
by either TG or PU-H71. Interestingly, although the overexpression of
Bcl-2 strongly prevented the apoptotic effects of TG, no protection
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centage of cells with dissipation of ΔΨm and activated caspase-3
were similar in parental and Bcl-2 overexpressing cells. These results
show that PU-H71 is able to kill cancer cells with elevated Bcl-2 pro-
tein level and consequently overcomes Bcl-2-mediated resistance to
apoptosis.3.6. PU-H71 requires Bax activation to trigger mitochondrial apoptosis in
cancer cells
vMIA has been demonstrated to inhibit apoptosis by binding to
Bax and sequestering it at the mitochondrial membrane as an inactive
oligomer [26]. These results, together with our ﬁndings that vMIA
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volvement of the pro-apoptotic protein Bax in response to PU-H71
treatment. HeLa cells were incubated with PU-H71 (1 μM) and the
level of the pro-apoptotic protein Bax was evaluated by western
blot. As depicted in Fig. 6A, a time-dependent increase of Bax expres-
sion was promoted by PU-H71 treatment. Not only is the induction of
apoptosis associated with an increased expression of Bax but it is also
associated with its activation and its mitochondrial translocation [27].
Immunoﬂuorescence experiments were therefore performed using the
6A7 antibody that speciﬁcally recognizes the active conformer of Bax
(Fig. 6B). As expected, no activated Bax was observed in the absence of
treatment (control). In the presence of PU-H71, the activation of Bax
was clearly visualized in apoptotic cells with condensed or fragmented
nuclei (white arrowheads). To further evaluate the involvement of Bax
in PU-H71-induced apoptosis, HCT116 cells deﬁcient for Bax expression
(HCT Bax−) were used. Parental HCT116 and HCT116 cells lacking Bax
were exposed to PU-H71 (1 μM) for 40 h and analyzed by ﬂow cytome-
try. In the absence of Bax, cells were protected fromPU-H71-induced loss
of ΔΨm (Fig. 6C), caspase-3 activation (Fig. 6D) and cell death (Fig. 6E).
Consequently, PU-H71-triggered apoptotic pathway requires the
presence and the activation of the pro-apoptotic protein Bax.3.7. Alkylating agents sensitize resistant cells to PU-H71 treatment
Previous studies have shown that co-treatment of cells with the
Hsp90 inhibitor geldanamycin or NVP-AUY922 and the alkylating
agents cisplatin or melphalan, widely used in anticancer chemo-
therapy, sensitizes cancer cells to apoptosis [28–30]. We therefore
investigated whether Bax-deﬁcient cells, which are resistant to
PU-H71, could be sensitized to apoptosis by co-treatment with
melphalan (MLP) or cisplatin (Cisp). Bax-deﬁcient HCT116 cells
were treated for 40 h with either MLP (25 μM) or Cisp (15 μM)
alone or in combination with PU-H71 (1 μM) and analyzed by
ﬂow cytometry. As expected, the incubation of Bax-deﬁcient cells
with PU-H71, MLP or Cisp alone led to a weak induction of mitochon-
drial alterations (Fig. 7A) and cell death (Fig. 7B) (about 10–15%
more than the control). Interestingly, the treatment of these cells
with PU-H71 in combination with either MLP or Cisp induced more
than a 2.5-fold increase in mitochondrial alterations and resulted in
enhanced cell death, compared to individual control. These ﬁndings
demonstrate that combined treatment with PU-H71 and the DNA
cross-linkers MLP or Cisp greatly sensitizes resistant cancer cells to
apoptosis.
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The main focus of this study was to explore the involvement of ER
stress and mitochondrial pathways in PU-H71-induced apoptosis and
to investigate the role of Bcl-2 and Bax in this process. The results
show that Hsp90 inhibition by PU-H71 induces cell death in the ﬁve
human cancer cell lines tested, at least in part, by inducing ER
stress-dependent activation of themitochondrial pathway of apoptosis.
We also found that PU-H71 overcomes Bcl-2-mediated resistance to ap-
optosis and showed that Bax-deﬁcient cells, which are resistant to
PU-H71, can be sensitized to apoptosis by co-treatment with cisplatin
or melphalan.
Treatment of HeLa cells with PU-H71 resulted in induction of ER
stress as demonstrated by robust increase in the expression of the
ER resident chaperones Grp78 and Grp94 (the ER Hsp90 paralog).
ER stress is sensed by three upstream proteins IRE1, ATF6 and PERK,
which activate different signaling pathways collectively termed UPR
[17]. PU-H71 was reported to induce XBP1 splicing in the myeloma
cell line RPMI-8226/DOX40, suggesting activation of the UPR [10]. In
HeLa cells, derived from solid tumor, we showed that PU-H71 inducedthe activation of the PERK/ATF4 and IRE1/XBP1 arms of the UPR.
These results indicate that this Hsp90 inhibitor activates different
branches of the UPR, which is consistent with the role of Hsp90 in sta-
bilizing protein conformation. We also demonstrated in ﬁve different
cancer cell lines, that the expression of the pro-apoptotic factor CHOP
was increased following PU-H71 treatment, showing that the ER stress
induced by this inhibitor is sufﬁcient to activate the pro-apoptotic arm
of the UPR. The transcription factor CHOP, up-regulated by the three
branches of the UPR, was the ﬁrst protein identiﬁed as a key mediator
of ER stress-induced apoptosis [31]. One proposed mechanism by
which prolonged activation of CHOP promotes apoptosis is through
down-regulation of the anti-apoptotic protein Bcl-2 and up-regulation
of the BH3-only protein Bim,which is necessary for Bax-mediatedmito-
chondrial permeabilization and apoptosis [17]. To the best of our
knowledge, our work is the ﬁrst to examine the role of Bcl-2 and Bax
in response to PU-H71. We showed that the expression level of Bcl-2
decreased in a time-dependent manner following PU-H71 treatment,
which is consistent with the up-regulation of CHOP expression. In addi-
tion, PU-H71 promoted the up-regulation of Bax and induced its activa-
tion as demonstrated by immunoﬂuorescence analysis. The ratio
010
20
30
40
50
60
+ MLP
PU-H71
+ Cisp
FD
A
 lo
w
 c
el
ls
 (%
)
**
**
**
&&&
&&&
###
***
***
0
10
20
30
40
50
Co. PU-H71 MLP Cisp PU-H71
D
iO
C6
(3)
 lo
w 
ce
lls
 (%
)
** **
**
&&&
&&&
###
***
***
A
B
+ MLP
PU-H71
+ Cisp
Co. PU-H71 MLP Cisp PU-H71
Fig. 7. Alkylating agents sensitize Bax-deﬁcient cells to PU-H71 treatment. (A, B)
HCT116 Bax-deﬁcient cells treated with 1 μM PU-H71, 25 μM melphalan (MLP) or
15 μM cisplatin (Cisp) alone and in combination (PU-H71+MLP or PU-H71+Cisp)
were analyzed by ﬂow cytometry for ΔΨm dissipation (A) and cell death (B). The
data represent mean±SD (n=3; **Pb0.01, ***Pb0.005 compared to control;
&&&Pb0.005 compared to PU-H71 alone; ###Pb0.005 compared to MLP alone; $$
$Pb0.005 compared to Cisp alone by Student's t-test).
1364 C. Gallerne et al. / Biochimica et Biophysica Acta 1833 (2013) 1356–1366between Bcl-2 and Bax proteins is known to form an apoptotic rheostat
which determines the sensitivity of cells to apoptosis [32]. Hence, our
data suggest that sustained ER stress promotes apoptosis by decreasing
Bcl-2/Bax ratio and thus provide amechanism bywhich PU-H71 can in-
duce themitochondrial pathway of apoptosis in cancer cells. Moreover,
under prolonged ER stress, IRE1 associates in a complexwith TRAF2 and
ASK1 to phosphorylate and activate JNK [17]. Upon activation, JNK can
phosphorylate and inhibit Bcl-2 and Bcl-xL and can also phosphorylate
and activate BH3-only proteins such as Bid and Bim [33], thereby
shifting the balance of Bcl-2 family toward apoptosis. Therefore, IRE1
and CHOP branches of the UPR, both activated by PU-H71, might have
additive effects on the regulation of Bcl-2 members and on the activation
of the mitochondrial pathway of apoptosis, a hypothesis that requires
further investigation.
CHOP has also been suggested to induce apoptosis by activating
calcium signaling pathways. Indeed, in vitro and in vivo data have
shown that, under ER stress, CHOP induces ERO1α which in turnactivates IP3R-mediated Ca2+ release [34]. We have previously
shown that following ER stress, Ca2+ released through IP3R accumu-
lates inmitochondria and promotes PTP-dependent alterations ofmito-
chondrial morphology and activation of the mitochondrial apoptotic
pathway [22]. Ca2+ transfer from ER to mitochondria is achieved at
speciﬁc microdomains [35], where both organelles are maintained in
close contact by physical links of protein nature, which were demon-
strated to increase in response to ER stress [36]. In our model, ultra-
structural studies revealed that, after PU-H71 treatment, the number
of contact sites between the ER and mitochondria was increased and
that mitochondria appeared more spherical in shape, swollen, devoid
of cristae and displayed local rupture of their membranes. These obser-
vations suggest that PU-H71 triggers a lethal crosstalk between the
perturbed ER and mitochondria, which activates the mitochondrial
pathway of apoptosis. In agreement with this idea, we found that
PU-H71 activates the mitochondrial apoptotic pathway by inducing
PTP opening, dissipation of ΔΨm, permeabilization of mitochondrial
membranes and release of cytochrome c into the cytosol. Upon release
frommitochondria, cytochrome c activates the proteolytic caspase cas-
cade [12]. Using caspase-3 ﬂuorogenic substrate and the general
caspase inhibitor zVAD, we demonstrated that Hsp90 inhibition by
PU-H71 induced a caspase-dependent apoptotic process. Different re-
ports have suggested that ER stress leads to calcium-dependent activa-
tion of calpains [37,38]. In our model, the pre-treatment of cells with
calpain inhibitors did not affect the extent of apoptosis induced by
PU-H71, suggesting that calpains are not involved in response to this
Hsp90 inhibitor. We also found that PU-H71 exerted no cytotoxicity in
human normal ﬁbroblasts, which is in agreement with previous studies
showing potent and long-lasting anti-tumor effects of PU-H71 in vivo
without toxicity to the host [7–9]. This lack of toxicity, coupled with
its apoptotic activity in cancer cells, suggests that PU-H71 acts preferen-
tially on cancer cells instead of normal cells. The absence of toxicity
against normal tissuesmay be explained by theﬁndings that the afﬁnity
of PU-H71 for Hsp90 is higher in cancer cells than in normal cells be-
cause PU-H71 binds preferentially to a subset of Hsp90 proteins
which is more abundant in cancer cells than in normal cells [39].
Anyway, the ability of PU-H71 to induce apoptosis in cancer cells
and its lack of toxicity toward normal cells make this purine scaffold
Hsp90 inhibitor an attractive antitumor agent.
Overexpression of the anti-apoptotic protein Bcl-2, which prevents
cells to undergo apoptosis, is frequently observed in human cancers
[40]. Thus, a major goal in cancer chemotherapy is to ﬁnd cytotoxic
agents that can efﬁciently induce apoptosis in cancer cells that express
high level of Bcl-2.We found thatmitochondrial alterations, caspase ac-
tivation and cell death were induced by PU-H71 to the same extent in
parental and Bcl-2 overexpressing cells. The observation that both cell
lines exhibited the same sensitivity toward PU-H71 suggests that this
Hsp90 inhibitor is able to overcome the resistance conferred by Bcl-2
in HeLa cells. In contrast to the effects observedwith PU-H71, apoptosis
induced by geldanamycin or 17-AAG was reduced by 85% and 65%,
respectively, in rat histiocytoma cells overexpressing Bcl-2 [21],
suggesting that these Hsp90 inhibitors are unable to overcome
Bcl-2-mediated resistance to apoptosis. Although the different re-
sponses to Hsp90 inhibitors may be explained by a species or cell
type speciﬁcity, it seems reasonable to propose that PU-H71 is a
more promising drug than geldanamycin or its derivatives for the
treatment of tumors that overexpress Bcl-2 and are resistant to con-
ventional chemotherapy.
Loss or inactivation of Bax is a mechanism of protection of cancer
cells against apoptosis and is often observed in cancers resistant to
chemotherapy. In this study, we demonstrated that knockout of Bax or
its neutralization by vMIA [26] impedes the dissipation of ΔΨm, the ac-
tivation of caspase-3 and apoptosis induced by PU-H71. Therefore, Bax
plays a pivotal role in the apoptotic signaling pathway triggered by
PU-H71 and its absence renders cells resistant to this Hsp90 inhibitor.
An approach commonly used to circumvent resistance of cells is
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target cancer cells. When used in combination with PU-H71, melphalan
or cisplatin, two conventional DNA-damaging drugs commonly used in
the treatment of cancer, were able to restore the sensitivity of resistant
cells to PU-H71-induced apoptosis. Consequently, the combined treat-
ment with PU-H71 and DNA damaging agents may overcome the resis-
tance to apoptosis and improve the elimination of Bax deﬁcient cells at
least in vitro. Other studies have reported enhancement of the
pro-apoptotic effects of Hsp90 inhibitors when used in combination
with cisplatin ormelphalan. For instance, inmultiplemyeloma,melpha-
lan was shown to increase apoptosis induced by the Hsp90 inhibitor
NVP-AUY922 [29]. Besides, geldanamycinwas demonstrated to increase
the sensitivity of osteosarcoma cells [28] and of resistant ovarian adeno-
carcinoma cells [30] to cisplatin. It was very recently reported that
co-treatment with 17-AAG and cisplatin synergistically enhances cyto-
toxicity in A549 lung carcinoma cells through down-regulation of the
cisplatin-induced thymidine phosphorylase expression and ERK1/2
and AKT activation [41]. Therefore, although the mechanisms by which
DNA damaging agents enhance the sensitivity of resistant cells to
Hsp90 inhibitors need further investigations, our results indicate that
the combination of PU-H71 with either melphalan or cisplatin may be
highly effective against Bax-deﬁcient tumors which are drug resistant.
In conclusion, our data show that the novel Hsp90 inhibitor
PU-H71 elicits an ER stress response which results in activation of
the mitochondrial pathway of apoptosis in different human cancer
cells. An important ﬁnding is that PU-H71 is able to induce apoptosis
in HeLa cells overexpressing Bcl-2, which are particularly resistant to
chemotherapy. The demonstration that combined treatment with either
melphalan or cisplatin sensitizes resistant cells to PU-H71 provides
grounds for the development of drug combination strategies using
PU-H71 and alkylating agent, in particular for the treatment of cancers re-
sistant to conventional therapy.
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